Cytomegalovirus (CMV) drug resistance, Next-Generation Sequencing, plasma

Alphabetical Test listing

Cytomegalovirus (CMV) drug resistance, Next-Generation Sequencing, plasma-994

  
Cytomegalovirus (CMV) drug resistance, Next-Generation Sequencing, plasma
  
994
  
LAB994
  
MSO
  
CMV by NGS
CMV Drug resistance
CMV sequencing
Cytomegalovirus antiviral resistance
UL97
UL54
Ganciclovir
Cidofovir
Foscarnet
  

Detecting variants in the cytomegalovirus genes, UL97 and UL54, which are associated with antiviral resistance

  

This test is not useful for the initial diagnosis of CMV infection

  
EDTA plasma
  

Lavender (EDTA), 4mL

  
1.2 mL
  
1.0 mL
  
  1. Spin
  2. Transfer plasma to a Screw cap transfer vial/tube (Mayo T465)
  3. Freeze
  

Screw cap transfer vial/tube (Mayo T465)

  

Frozen (preferred) – 30 days

Refrigerated – 14 days

Ambient – NO ­

  
14 days
  
Mayo Clinic Laboratories (CMVNG): R-NX
  
Mo - Fr
  
7 – 14 days
  

Next-Generation Sequencing (NGS)

  

None detected/not predicted

  

Next-generation sequencing testing may be indicated if a patient with known CMV infection has a rising or stabilizing viral load while on antiviral therapy. This test can assist in determining whether CMV is present that has acquired variants associated with antiviral resistance, and should only be performed on patients who have had a recent (ie, within the previous 7 days) CMV quantitative plasma viral load of 500 IU/mL or more.

  
87910
  
03/31/2021
  
04/12/2021